Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immucell ( (ICCC) ) has shared an update.
On April 13, 2026, ImmuCell announced the appointment of animal health veteran Dr. Gilles Guillemette and biologics and manufacturing specialist Dr. Anthony DiMarco to its Board of Directors, effective April 15, 2026. The company is restructuring its governance to a smaller, 7-member board comprising six independent directors and the CEO, and is forming a new Strategy and Technology Committee to guide innovation and technical direction.
The board changes are accompanied by the planned retirement of several current directors, including non-independent members, while some will continue in executive roles, underscoring a shift toward greater board independence. ImmuCell emphasized that the new board composition and committee structure are intended to support improvements in manufacturing yield and capacity and to drive innovation-led growth of its flagship First Defense® line, potentially strengthening its competitive position in the animal health biologics market.
Spark’s Take on ICCC Stock
According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.
The score is held back primarily by weak and uncertain financial quality (net losses and problematic/unclear cash flow and equity data) and bearish technicals (below major moving averages with weak momentum). These are partially offset by a more positive earnings-call outlook highlighting margin expansion, an operating-income turnaround, and capacity plans that could support growth if executed.
To see Spark’s full report on ICCC stock, click here.
More about Immucell
ImmuCell Corporation is an animal health biologics company serving the dairy and beef industries with practical, science-based solutions to improve the survivability, health, and long-term performance of calves. Its primary product line, First Defense®, is a colostrum-derived, orally delivered antibody treatment that provides immediate immunity against major viral and bacterial causes of scours in neonatal calves, a leading cause of morbidity and mortality worldwide.
The company focuses on products that enhance calf health and productivity, targeting dairy and beef producers seeking to reduce disease-related losses and improve herd performance. ImmuCell positions itself in the livestock health market with an emphasis on biologics, manufacturing efficiency, and innovation around hyperimmune colostrum technology to support growth of its First Defense® franchise.
Average Trading Volume: 17,688
Technical Sentiment Signal: Strong Buy
Current Market Cap: $64.01M
Find detailed analytics on ICCC stock on TipRanks’ Stock Analysis page.